Head to Head Survey: SiBone (SIBN) & The Competition

SiBone (NASDAQ:SIBN) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its rivals? We will compare SiBone to similar companies based on the strength of its earnings, analyst recommendations, dividends, valuation, institutional ownership, risk and profitability.

Insider and Institutional Ownership

98.1% of SiBone shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 4.0% of SiBone shares are held by company insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares SiBone and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
SiBone	$200.93 million	-$18.90 million	-78.19
SiBone Competitors	$1.89 billion	$137.77 million	9.47

SiBone’s rivals have higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

SiBone has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, SiBone’s rivals have a beta of 2.70, suggesting that their average stock price is 170% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for SiBone and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1	0	7	0	2.75
SiBone Competitors	4270	10539	18313	828	2.46

SiBone presently has a consensus price target of $25.00, suggesting a potential upside of 3.14%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.11%. Given SiBone’s rivals higher possible upside, analysts clearly believe SiBone has less favorable growth aspects than its rivals.

Profitability

This table compares SiBone and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SiBone	-6.20%	-7.57%	-5.55%
SiBone Competitors	-276.78%	-149.08%	-21.73%

Summary

SiBone rivals beat SiBone on 7 of the 13 factors compared.

SiBone Company Profile

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.